

Giorgio L Colombo

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5167633/publications.pdf>

Version: 2024-02-01

50
papers

1,561
citations

516710
16
h-index

315739
38
g-index

54
all docs

54
docs citations

54
times ranked

2540
citing authors

#	ARTICLE	IF	CITATIONS
1	Cost Analysis of Platelet Transfusion in Italy for Patients with Chronic Liver Disease and Associated Thrombocytopenia Undergoing Elective Procedures. ClinicoEconomics and Outcomes Research, 2022, Volume 14, 205-220.	1.9	2
2	Utilization of Healthcare Resources in Osteoarthritis: A Cost of Illness Analysis Based on Real-World Data in Italy. Therapeutics and Clinical Risk Management, 2021, Volume 17, 345-356.	2.0	13
3	Economic Impact of COVID-19 Lockdown on Italian NHS: Focus on Diabetes Mellitus. ClinicoEconomics and Outcomes Research, 2021, Volume 13, 503-518.	1.9	4
4	Cost-Utility Analysis of Saxagliptin/Dapagliflozin Versus Gliclazide and Insulin Glargine: Economic Implications of the Outcomes of the CVD-Real Studies I and II. Health Services Insights, 2020, 13, 117863292092998.	1.3	1
5	<p>Omalizumab for Severe Allergic Asthma Treatment in Italy: A Cost-Effectiveness Analysis from PROXIMA Study</p>. Risk Management and Healthcare Policy, 2020, Volume 13, 43-53.	2.5	11
6	<p>Economic Evaluation of Dulaglutide vs Traditional Therapies: Implications of the Outcomes of the Rewind Study</p>. ClinicoEconomics and Outcomes Research, 2020, Volume 12, 177-189.	1.9	9
7	Topical Sunscreen Application Preventing Skin Cancer: Systematic Review. Cosmetics, 2019, 6, 42.	3.3	12
8	<p>Cost-consequence analysis for human recombinant growth hormone (r-hGH) treatment administered via different devices in children with growth hormone deficiency in Italy</p>. ClinicoEconomics and Outcomes Research, 2019, Volume 11, 525-537.	1.9	11
9	Omalizumab and long-term quality of life outcomes in patients with moderate-to-severe allergic asthma: a systematic review. Therapeutic Advances in Respiratory Disease, 2019, 13, 175346661984135.	2.6	10
10	Shadow cost of oral corticosteroids-related adverse events: AÂpharmacoeconomic evaluation applied to real-life data fromÂtheÂSevereÂAsthma Network in Italy (SANI) registry. World Allergy Organization Journal, 2019, 12, 100007.	3.5	82
11	Budget impact model of secukinumab for the treatment of moderate-to-severe psoriasis, psoriatic arthritis, and ankylosing spondylitis in Italy: a cross-indication initiative. ClinicoEconomics and Outcomes Research, 2018, Volume 10, 477-491.	1.9	9
12	The preventive effect on respiratory tract infections of Oscilloccinum<sup>&reg</sup>. A cost-effectiveness analysis. ClinicoEconomics and Outcomes Research, 2018, Volume 10, 75-82.	1.9	2
13	Cost-minimization analysis of degludec/liraglutide versus glargine/aspart: economic implications of the DUAL VII study outcomes. ClinicoEconomics and Outcomes Research, 2018, Volume 10, 413-421.	1.9	7
14	Effects of Deep Versus Moderate Neuromuscular Blockade in Laparoscopic Gynecologic Surgery on Postoperative Pain and Surgical Conditions: Protocol for a Randomized Controlled Trial. JMIR Research Protocols, 2018, 7, e131.	1.0	1
15	Reduced adherence to antiretroviral therapy is associated with residual low-level viremia. Journal of Pragmatic and Observational Research, 2017, Volume 8, 91-97.	1.5	16
16	Adherence in ulcerative colitis: an overview. Patient Preference and Adherence, 2017, Volume 11, 297-303.	1.8	41
17	Impact of substitution among generic drugs on persistence and adherence: A retrospective claims data study from 2 Local Healthcare Units in the Lombardy Region of Italy. Atherosclerosis Supplements, 2016, 21, 1-8.	1.2	19
18	Patterns of treatment and costs of intermediate and advanced hepatocellular carcinoma management in four Italian centers. Therapeutics and Clinical Risk Management, 2015, 11, 1603.	2.0	12

#	ARTICLE	IF	CITATIONS
19	Economic burden of Clostridium difficile in five hospitals of the Florence health care system in Italy. Risk Management and Healthcare Policy, 2015, 8, 207.	2.5	6
20	Cost-effectiveness analysis of antiretroviral therapy in a cohort of HIV-infected patients starting first-line highly active antiretroviral therapy during 6 years of observation. Patient Related Outcome Measures, 2015, 6, 53.	1.2	2
21	Economic and outcomes consequences of TachoSil®: a systematic review. Vascular Health and Risk Management, 2014, 10, 569.	2.3	39
22	Cost-effectiveness analysis on the use of rFSH + rLH for the treatment of anovulation in hypogonadotropic hypogonadal women. Therapeutics and Clinical Risk Management, 2014, 10, 479.	2.0	8
23	Cost analysis of initial highly active antiretroviral therapy regimens for managing human immunodeficiency virus-infected patients according to clinical practice in a hospital setting. Therapeutics and Clinical Risk Management, 2013, 10, 9.	2.0	12
24	Antiretroviral therapy in HIV-infected patients: a proposal to assess the economic value of the single-tablet regimen. ClinicoEconomics and Outcomes Research, 2013, 5, 59.	1.9	24
25	Economic evaluation of initial antiretroviral therapy for HIV-infected patients: an update of Italian guidelines. ClinicoEconomics and Outcomes Research, 2013, 5, 489.	1.9	13
26	A cost-of-illness study of spina bifida in Italy. ClinicoEconomics and Outcomes Research, 2013, 5, 309.	1.9	4
27	Off-Patent Generic Medicines vs. Off-Patent Brand Medicines for Six Reference Drugs: A Retrospective Claims Data Study from Five Local Healthcare Units in the Lombardy Region of Italy. PLoS ONE, 2013, 8, e82990.	2.5	21
28	Generic vs brand originator alendronate: analysis of persistence and compliance in five Local Healthcare Units in the Lombardy Region of Italy. Clinical Cases in Mineral and Bone Metabolism, 2013, 10, 195-8.	1.0	5
29	The burden of endometriosis: costs and quality of life of women with endometriosis and treated in referral centres. Human Reproduction, 2012, 27, 1292-1299.	0.9	732
30	Economic comparison of capecitabine + oxaliplatin and 5-fluorouracil + oxaliplatin in the adjuvant treatment of colon cancer. Cancer Management and Research, 2012, 4, 99.	1.9	13
31	Antidiabetic therapy in real practice: indicators for adherence and treatment cost. Patient Preference and Adherence, 2012, 6, 653.	1.8	23
32	Burden of Crohn's disease: economics and quality of life aspects in Italy. ClinicoEconomics and Outcomes Research, 2012, 4, 209.	1.9	13
33	Cost-effectiveness analysis of HIV treatment in the clinical practice of a public hospital in northern Italy. Therapeutics and Clinical Risk Management, 2012, 8, 377.	2.0	8
34	Acamprosate in the treatment of alcoholism: a budget impact analysis for the National Health Service in Italy. Substance Abuse and Rehabilitation, 2012, 3, 73.	4.8	3
35	Calcipotriol and betamethasone dipropionate in the treatment of mild-to-moderate psoriasis: a cost-effectiveness analysis of the ointment versus gel formulation. ClinicoEconomics and Outcomes Research, 2012, 4, 261.	1.9	14
36	Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C. Hepatology, 2012, 56, 850-860.	7.3	97

#	ARTICLE	IF	CITATIONS
37	Cost and appropriateness of treating asthma with fixed-combination drugs in local health care units in Italy. ClinicoEconomics and Outcomes Research, 2012, 4, 375.	1.9	7
38	Cost-effectiveness analysis of initial HIV treatment under Italian guidelines. ClinicoEconomics and Outcomes Research, 2011, 3, 197.	1.9	24
39	A cost-effectiveness analysis of different therapies in patients with chronic hepatitis B in Italy. ClinicoEconomics and Outcomes Research, 2011, 3, 37.	1.9	22
40	Cost–utility analysis of prophylaxis versus treatment on demand in severe hemophilia A. ClinicoEconomics and Outcomes Research, 2011, 3, 55.	1.9	33
41	A cost–utility analysis of etanercept for the treatment of moderate-to-severe psoriasis in Italy. ClinicoEconomics and Outcomes Research, 2009, 1, 53.	1.9	15
42	Cost-effectiveness of the real-world use of drug-eluting stents at 9-month follow-up: results from the Sicilian DES Registry. Journal of Cardiovascular Medicine, 2009, 10, 322-329.	1.5	3
43	Cost-effectiveness analysis of electrochemotherapy with the Cliniporatorâ„¢ vs other methods for the control and treatment of cutaneous and subcutaneous tumors. Therapeutics and Clinical Risk Management, 2008, Volume 4, 541-548.	2.0	48
44	An economic evaluation of aripiprazole vs olanzapine adapted to the Italian setting using outcomes of metabolic syndrome and risk for diabetes in patients with schizophrenia. Neuropsychiatric Disease and Treatment, 2008, 4, 967.	2.2	12
45	Candesartan in heart failure: assessment of reduction in mortality and morbidity (CHARM) and resource utilization and costs in Italy. Vascular Health and Risk Management, 2008, 4, 223-234.	2.3	11
46	Cost-Effectiveness of Adjuvanted Influenza Vaccination of Healthy Children 6 to 60 Months of Age. Hum Vaccin, 2007, 3, 14-22.	2.4	41
47	Cost-benefit analysis of influenza vaccination in a public healthcare unit. Therapeutics and Clinical Risk Management, 2006, 2, 219-226.	2.0	31
48	Indagine sulla diffusione della farmacoconomia nellâ€™industria farmaceutica che opera in Italia. Pharmacoeconomics Italian Research Articles, 2001, 3, 91-103.	0.2	1
49	Analisi costi-benefici di una strategia vaccinale antinfluenzale condotta presso una societÃ del gruppo ENI (Snamprogetti). Pharmacoeconomics Italian Research Articles, 2001, 3, 71-80.	0.2	6
50	I costi nella gestione del paziente con dispepsia funzionale. Pharmacoeconomics Italian Research Articles, 2000, 2, 29-42.	0.2	3